drugset
drugset / Trial / NCT02019394

Absolute Bioavailability of Lu AE58054 in Healthy Subjects

NCT02019394 ↗

Phase 1 Completed 10 enrolled H. Lundbeck A/S
NaSingle-groupOpen-label

Summary

To determine the absolute bioavailability of the Lu AE58054 tablet formulation at steady state

Timeline

Start
2013-12
Primary completion
2014-02
Completion
—

Drugs

EvaluationDrugModalityDoseRoute
Subject Idalopirdine Small molecule 90 ug Oral
Subject Idalopirdine Small molecule 90 mg Oral

Indications

No indication recorded.